companies innovating in obesity treatment glp-1 drugs 2025 Unpacking $100B+ Market Opportunity: What It Means for Biopharma, Payers, and Providers Next-Generation GLP-1 Innovation Could Unlock
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 127.King A, Miller EM
Symptoms include shakiness, sweating, confusion, rapid heartbeat, and in severe cases, loss of consciousness
The list of FDA-approved indications for this class of medication has grown as of late (and currently includes type 2 diabetes, obesity, cardiovascular event risk reduction, obstructive sleep apnea, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease), and areas of interest for potential future indications are just as long and farreaching
China has also begun to pay attention to the risk of thyroid cancer induced by GLP-1RA, and this warning has been added to the drug instructions of some GLP-1RAs
Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
As these drugs gain momentum, we know we could see a rapid increase for their demand, given their potential to treat many different indications
